Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ribi ImmunoChem Research Inc.

Division of GlaxoSmithKline PLC

Latest From Ribi ImmunoChem Research Inc.

Vaccines Enter the New Age of Adjuvants

The US vaccine industry is a year away from a wave of new, more effective and longer-lasting adjuvant-enhanced products. The technology promises added protection to patients-and extra proprietary rights to product marketers.

BioPharmaceutical Regulation

Living with Limits: Device and Biotech Venture Capital

Lacking exits from either IPOs or acquisitions, squeezing returns out of biotech and device start-ups has become an increasingly difficult game. Many generalist VC firms have fled to the far more lucrative business of Internet and IT investing, particularly since both health care and IT have become far more technologically complex. Thus specialists have been taking over a much greater percentage of health care dealmaking, though shunning most of the high-risk biotech and device investing of the 80s and 90s. Their investments begin with a clearly defined, and sometimes pre-arranged, exit.

BioPharmaceutical Medical Device

Biotech Consolidation: Even News is No News

The only thing more noteworthy about the recent biotech M&A is than its volume is the silence that surrounds it: from Wall Street, the press, and Big Pharma. The problem is the consolidations themselves: largely intra-biotech affairs. Unless Big Pharma gets involved--and they've shown no interest in doing so--investors aren't going to get paid in what they want most out of an acquisition: liquid currency.

BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • GlaxoSmithKline PLC
  • Senior Management
  • Robert E Ivy, Chmn., Pres. & CEO
    Vern D Child, VP, Fin. & Treas.
    Charles Richardson, PhD, VP, Pharmaceutical Discovery
    John L Cantrell, PhD, EVP
    Gary T Elliott, PhD, VP, Pharmaceutical Dev.
    Gary T Von Eschen, PhD, VP, Clinical & Regulatory Affairs
  • Contact Info
  • Ribi ImmunoChem Research Inc.
    Phone: (406) 363-6214
    553 Old Corvallis Rd.
    Hamilton, MT 59840-3131